blindness from glp 1 with NAION and GLP1s: Rare Cause of Linked to Medication GLP-1 Receptor Agonists and vision

Just know much of the published data comes from manufacturer-sponsored studies

Combination protocols are often ideal: when symptoms overlap, NAD and a targeted peptide can address systemic and specific concerns simultaneously

It depends on how severe the deficiency is, the dose, and how the body responds

documented efficacy in improving desire scores and reducing distress associated with low libido Low libido in postmenopausal women: off-label use investigated where hormonal changes have reduced sexual desire and standard hormone therapy has not fully addressed the desire component Low sexual desire and erectile dysfunction in men: off-label use investigated for men where low libido (desire component) coexists with erectile difficulty, either as monotherapy or alongside PDE5 inhibitors Sexual dysfunction with psychological or stress-related components: PT-141's central mechanism may be particularly relevant where desire is suppressed by psychological factors rather than purely vascular ones Patients who have not responded adequately to PDE5 inhibitors alone: PT-141 adds the central desire component that PDE5i do not address PT-141 is the only FDA-approved medication that treats low sexual desire through a central neural mechanism rather than a peripheral vascular one

GHK-Cu is studied for its biphasic regulation of MMPsstimulating them during active repair while inhibiting excessive activity that could cause tissue damage

Kachi T